Interacciones de Fulvestrant

Fulvestrant (Faslodex), estrógeno, tiene 188 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 22; moderadas: 111; leves: 39; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 16. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (22)

  • Ácido tranexámicoantifibrinolíticoGrave

    Concomitant use of combined hormonal contraceptives ( 4.1 ) (etiqueta de Ácido tranexámico, Contraindicaciones)

  • AcitretinaretinoideGrave

    Primary forms of contraception include: tubal ligation, partner’s vasectomy, intrauterine devices, birth control pills, and injectable/implantable/insertable/topical hormonal birth control products. (etiqueta de Acitretina, Advertencia en recuadro)

  • Anastrozolinhibidor de la aromatasaGrave

    Estrogen Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action. (etiqueta de Anastrozol, Interacciones medicamentosas)

  • Desogestrel y etinilestradiolanticonceptivo oralGrave

    …surgery with prolonged immobilization • Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia • Undiagnosed abnormal genital bleeding • Cholestatic jaundice of pregnancy or jaundice with prior pill use • Acute or chronic hepatocellular disease with… (etiqueta de Desogestrel y etinilestradiol, Contraindicaciones)

  • EstradiolestrógenoGrave

    CARDIOVASCULAR AND OTHER RISKS Estrogens and progestins should not be used for the prevention of cardiovascular disease [see WARNINGS , Cardiovascular disorders ]. (etiqueta de Estradiol, Advertencia en recuadro)

  • Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. (etiqueta de Estradiol y noretisterona, Advertencia en recuadro)

  • Estrógenos conjugadosestrógenoGrave

    (See CLINICAL STUDIES and WARNINGS, Probable Dementia and PRECAUTIONS, Geriatric Use .) In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. (etiqueta de Estrógenos conjugados, Advertencia en recuadro)

  • WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA • Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1) ] • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (etiqueta de Estrógenos conjugados y bazedoxifeno, Advertencia en recuadro)

  • (See WARNINGS, Malignant Neoplasms, Endometrial Cancer. ) CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (etiqueta de Estrógenos esterificados y metiltestosterona, Advertencia en recuadro)

  • Exemestanoinhibidor de la aromatasaGrave

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (etiqueta de Exemestano, Advertencias y precauciones)

  • GriseofulvinaantifúngicoGrave

    Women taking estrogen-containing oral contraceptives may be at increased risk of becoming pregnant while on griseofulvin (see also PRECAUTIONS, Drug Interactions ) . (etiqueta de Griseofulvina, Contraindicaciones)

  • Hierba de San Juan (hipérico)Plantas medicinales y suplementosGrave

    La hierba de San Juan (hipérico) puede hacer que las píldoras anticonceptivas sean menos eficaces. (NCCIH, St. John's Wort)

  • Levonorgestrel y etinilestradiolanticonceptivo oralGrave

    …neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches [see Warnings and Precautions (5.7) ] Current or history of breast cancer or other estrogen- or progestin-sensitive cancer Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis [see Warnings and Precautions (5.2) ] Undiagnosed abnormal uterine bleeding… (etiqueta de Levonorgestrel y etinilestradiol, Contraindicaciones)

  • Mifepristonainhibidor de CYP3A4Grave

    Hormonal contraceptives: Do not use with mifepristone ( 7.6 ). (etiqueta de Mifepristona, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Grave

    Sensitive CYP3A substrates including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index. (etiqueta de Mitapivat, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    Hormonal contraceptives: Avoid concomitant use with LYSODREN. (etiqueta de Mitotano, Interacciones medicamentosas)

  • Breast cancer or other estrogen- or progestin-sensitive cancer ( 4 ) (etiqueta de Norelgestromina y etinilestradiol, Contraindicaciones)

  • NoretisteronaprogestágenoGrave

    CONTRAINDICATIONS Progestin-only oral contraceptives (POPs) should not be used by women who currently have the following conditions: • Known or suspected pregnancy • Known or suspected carcinoma of the breast. (etiqueta de Noretisterona, Contraindicaciones)

  • ProgesteronaprogestágenoGrave

    Coronary Heart Disease In women 50 to 59 years of age, the WHI estrogen plus progestin trial reported a relative risk for coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) of 1.34 (95% CI, 0.82, 2.19) for CE/MPA compared placebo, with a risk difference of 5 per 10,000 WYs (23 versus 17). (etiqueta de Progesterona, Advertencias)

  • Raloxifenomodulador selectivo de los receptores de estrógenosGrave

    Concomitant Use with Systemic Estrogens : Not recommended. (etiqueta de Raloxifeno, Advertencias y precauciones)

  • Tizanidinarelajante muscularGrave

    Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (etiqueta de Tizanidina, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    John's Wort (CYP450 inducer; P-gp inducer) Significantly Reduced Contraindicated Oral Contraceptives containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) Increased Monitoring for adverse reactions and toxicity related to voriconazole is recommended for concomitant administration with oral contraceptives. (etiqueta de Voriconazol, Interacciones medicamentosas)

Interacciones moderadas (111)

  • Drugs Affecting Lipid Metabolism Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and hence may counteract the effectiveness of URSO 250 and URSO Forte. (etiqueta de Ácido ursodesoxicólico, Interacciones medicamentosas)

  • Ácido valproicoanticonvulsivoModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives: Monitoring of valproate concentrations is recommended (7.1) (etiqueta de Ácido valproico, Interacciones medicamentosas)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (etiqueta de Alogliptina y metformina, Interacciones medicamentosas)

  • AminofilinametilxantinaModerada

    Estrogen Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. (etiqueta de Aminofilina, Interacciones medicamentosas)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    • Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.5 ). (etiqueta de Amlodipino y atorvastatina, Interacciones medicamentosas)

  • Amoxicilinaantibiótico del grupo de las penicilinasModerada

    Amoxicillin may reduce the efficacy of oral contraceptives. (etiqueta de Amoxicilina, Interacciones medicamentosas)

  • Amoxicilina y ácido clavulánicoantibiótico del grupo de las penicilinasModerada

    Amoxicillin and Clavulanate Potassium Extended Release Tablets may reduce efficacy of oral contraceptives. (etiqueta de Amoxicilina y ácido clavulánico, Interacciones medicamentosas)

  • Ampicilinaantibiótico del grupo de las penicilinasModerada

    Oral Contraceptives : May be less effective and increased breakthrough bleeding may occur. (etiqueta de Ampicilina, Interacciones medicamentosas)

  • ApixabánanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • Aprepitantinhibidor de CYP3A4Moderada

    Hormonal Contraceptives : Efficacy of contraceptives may be reduced during and for 28 days following administration of aprepitant. (etiqueta de Aprepitant, Advertencias y precauciones)

  • ArgatrobánanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • AtazanavirantirretroviralModerada

    Hormonal contraceptives: ethinyl estradiol and norgestimate or norethindrone ↓ ethinyl estradiol ↑ norgestimate c ↑ ethinyl estradiol ↑ norethindrone d Use caution if considering coadministration of oral contraceptives with REYATAZ or REYATAZ with ritonavir. (etiqueta de Atazanavir, Interacciones medicamentosas)

  • AtorvastatinaestatinaModerada

    • Oral Contraceptives: May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive ( 7.3 ). (etiqueta de Atorvastatina, Interacciones medicamentosas)

  • BivalirudinaanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Moderada

    Hormonal contraceptives: TRACLEER use decreases contraceptive exposure and reduces effectiveness ( 7.2 ). (etiqueta de Bosentán, Interacciones medicamentosas)

  • CabotegravirantirretroviralModerada

    Drugs without Clinically Significant Interactions with Cabotegravir Based on drug interaction study results, the following drugs can be coadministered with cabotegravir without a dose adjustment: etravirine, midazolam, oral contraceptives containing levonorgestrel and ethinyl estradiol, rifabutin, and rilpivirine [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Cabotegravir, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    EQUETRO can reduce the effectiveness of hormonal contraceptives. (etiqueta de Carbamazepina, Advertencias y precauciones)

  • CenobamatoanticonvulsivoModerada

    Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. (etiqueta de Cenobamato, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    …itraconazole clarithromycin Amiodarone verapamil ketoconazole erythromycin Bromocriptine voriconazole quinupristin/ dalfopristin colchicine danazol imatinib metoclopramide nefazodone oral contraceptives HIV Protease Inhibitors The HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, and saquinavir) are known to inhibit cytochrome P-450 3A and thus could… (etiqueta de Ciclosporina, Interacciones medicamentosas)

  • Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (etiqueta de Cloruro de calcio, Interacciones medicamentosas)

  • Cocaínaanestésico localModerada

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (etiqueta de Cocaína, Interacciones medicamentosas)

  • Colesevelamsecuestrador de ácidos biliaresModerada

    Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (etiqueta de Colesevelam, Interacciones medicamentosas)

  • Colestiraminasecuestrador de ácidos biliaresModerada

    Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (etiqueta de Colestiramina, Interacciones medicamentosas)

  • Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis. (etiqueta de Coriogonadotropina alfa, Advertencias)

  • DabigatránanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • DarunavirantirretroviralModerada

    Hormonal contraceptives : Effective alternative (non-hormonal) contraceptive method or a barrier method of contraception is recommended [see Use in Specific Populations (8.3) ] . ethinyl estradiol, norethindrone, drospirenone ↓ ethinyl estradiol ↓ norethindrone drospirenone: effects unknown For co-administration with drospirenone, clinical monitoring is recommended… (etiqueta de Darunavir, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralModerada

    Hormonal contraceptives: Additional or alternative (non-hormonal) forms of contraception should be considered when estrogen-containing contraceptives are co-administered with PREZCOBIX or PREZCOBIX PED [see Use in Specific Populations (8.3) ] . drospirenone/ethinylestradiol ↑ drospirenone ↓ ethinylestradiol For co-administration with drospirenone, clinical monitoring… (etiqueta de Darunavir y cobicistat, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroModerada

    …budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil,… (etiqueta de Deferasirox, Interacciones medicamentosas)

  • Deutetrabenazinainhibidor de VMAT2Moderada

    Chronic increase in serum prolactin levels (although not evaluated in the AUSTEDO XR, AUSTEDO, or tetrabenazine development programs) has been associated with low levels of estrogen and increased risk of osteoporosis. (etiqueta de Deutetrabenazina, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    (‎ 7.1 ) • Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (etiqueta de Dexametasona, Interacciones medicamentosas)

  • Divalproato de sodio (valproato)anticonvulsivoModerada

    Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives, methotrexate: Monitoring of valproate concentrations is recommended ( 7.1 ) (etiqueta de Divalproato de sodio (valproato), Interacciones medicamentosas)

  • DolutegravirantirretroviralModerada

    …following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Dolutegravir, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding. (etiqueta de Drospirenona y etinilestradiol, Interacciones medicamentosas)

  • EdoxabánanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • For patients with CF taking hormonal contraceptives who develop rash, consider interrupting TRIKAFTA and hormonal contraceptives. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Interacciones medicamentosas)

  • Hormonal Contraceptives: drospirenone/ethinyl estradiol levonorgestrel norgestimate/ethinyl estradiol ↑ drospirenone ↑ norgestimate ↑ levonorgestrel ↓ ethinyl estradiol Additional or alternative non-hormonal forms of contraception should be considered when estrogen based contraceptives are coadministered with GENVOYA. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

  • EnoxaparinaanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • EslicarbazepinaanticonvulsivoModerada

    Hormonal Contraceptives: APTIOM may decrease the effectiveness of hormonal contraceptives. (etiqueta de Eslicarbazepina, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralModerada

    Interference of Fulvestrant with Serum Estradiol Immunoassays Due to structural similarity of fulvestrant and estradiol, fulvestrant can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels [see Warnings and Precautions (5.4) ] . (etiqueta de Fulvestrant, Interacciones medicamentosas)

  • Effects of CHCs on Other Drugs CHCs containing ethinyl estradiol may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (etiqueta de Etonogestrel y etinilestradiol, Interacciones medicamentosas)

  • FelbamatoanticonvulsivoModerada

    Effects of Felbatol ® on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 µg ethinyl estradiol and 75 µg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive… (etiqueta de Felbamato, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    …omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antacids… (etiqueta de Fenitoína, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCModerada

    Oral Contraceptives Clinical Impact Co-administration of multiple-dose phentermine and topiramate extended-release capsules 15 mg/92 mg once daily with a single dose of oral contraceptive containing 35 µg ethinyl estradiol (estrogen component) and 1 mg norethindrone (progestin component), in obese otherwise healthy volunteers, decreased the exposure of ethinyl… (etiqueta de Fentermina y topiramato, Interacciones medicamentosas)

  • Flibanserinadepresor del SNCModerada

    Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (etiqueta de Flibanserina, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    Oral contraceptives Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. (etiqueta de Fluconazol, Interacciones medicamentosas)

  • FludrocortisonacorticosteroideModerada

    Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (etiqueta de Fludrocortisona, Interacciones medicamentosas)

  • FolitropinaModerada

    Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of overstimulation [see Warnings and Precautions (5.8) ] . (etiqueta de Folitropina, Advertencias y precauciones)

  • FondaparinuxanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • FosamprenavirantirretroviralModerada

    Fosamprenavir calcium: ↓ Amprenavir ↓ Ethinyl estradiol May lead to loss of virologic response. a Fosamprenavir calcium/ritonavir: ↓ Ethinyl estradiol Increased risk of transaminase elevations. (etiqueta de Fosamprenavir, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    Hormonal Contraceptives: Efficacy of contraceptives may be reduced during treatment and for 1 month following administration of the last dose of either fosaprepitant or oral aprepitant. (etiqueta de Fosaprepitant, Advertencias y precauciones)

  • FosfenitoínaanticonvulsivoModerada

    …omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic… (etiqueta de Fosfenitoína, Interacciones medicamentosas)

  • GabapentinaanticonvulsivoModerada

    Oral Contraceptive Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg three times a day; N=13). (etiqueta de Gabapentina, Interacciones medicamentosas)

  • GlimepiridasulfonilureaModerada

    …somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (etiqueta de Glimepirida, Interacciones medicamentosas)

  • GlipizidasulfonilureaModerada

    …GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (etiqueta de Glipizida, Interacciones medicamentosas)

  • GoserelinaModerada

    Tumor Flare Phenomenon Initially, ZOLADEX, like other GnRH agonists, causes transient increases in serum levels of testosterone in men with prostate cancer, and estrogen in women with breast cancer. (etiqueta de Goserelina, Advertencias y precauciones)

  • HeparinaanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • • Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (etiqueta de Hialuronidasa, Interacciones medicamentosas)

  • HidrocortisonacorticosteroideModerada

    Intervention: Concomitant use of estrogen/estrogen containing products may require an increase in the ALKINDI SPRINKLE dose. (etiqueta de Hidrocortisona, Interacciones medicamentosas)

  • Insulina aspartainsulinaModerada

    …Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (etiqueta de Insulina asparta, Interacciones medicamentosas)

  • Insulina degludecinsulinaModerada

    …Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (etiqueta de Insulina degludec, Interacciones medicamentosas)

  • Insulina detemirinsulinaModerada

    …Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (etiqueta de Insulina detemir, Interacciones medicamentosas)

  • Insulina glarginainsulinaModerada

    …Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (etiqueta de Insulina glargina, Interacciones medicamentosas)

  • Insulina lisproinsulinaModerada

    …Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline),… (etiqueta de Insulina lispro, Interacciones medicamentosas)

  • LamotriginaanticonvulsivoModerada

    Concomitant Use with Estrogen-Containing Products, Including Oral Contraceptives Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Lamotrigina, Advertencias y precauciones)

  • LeflunomidainmunosupresorModerada

    Effect on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. (etiqueta de Leflunomida, Interacciones medicamentosas)

  • LenalidomidaModerada

    ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision in patients receiving REVLIMID [see Drug Interactions (7.2) ]. (etiqueta de Lenalidomida, Advertencias y precauciones)

  • Levotiroxinahormona tiroideaModerada

    …1: Drugs That May Alter T 4 and Triiodothyronine (T 3 ) Serum Transport Without Effecting Free Thyroxine (FT 4 ) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. (etiqueta de Levotiroxina, Interacciones medicamentosas)

  • Levotiroxina y liotironinahormona tiroideaModerada

    Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

  • Liotironinahormona tiroideaModerada

    Table 2: Drugs That May Alter Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. (etiqueta de Liotironina, Interacciones medicamentosas)

  • LomitapidaModerada

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etiqueta de Lomitapida, Advertencias y precauciones)

  • Lorlatinibinductor de CYP3A4Moderada

    Advise females of reproductive potential to use an effective non-hormonal method of contraception, since LORBRENA can render hormonal contraceptives ineffective, during treatment with LORBRENA and for at least 6 months after the final dose. (etiqueta de Lorlatinib, Advertencias y precauciones)

  • MedroxiprogesteronaprogestágenoModerada

    Loss of Bone Mineral Density Use of MPA Injectable Suspension, USP reduces serum estrogen levels and is associated with significant loss of bone mineral density (BMD). (etiqueta de Medroxiprogesterona, Advertencias y precauciones)

  • MetilprednisolonacorticosteroideModerada

    Estrogens, including oral contraceptives : Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Metilprednisolona, Interacciones medicamentosas)

  • MicofenolatoinmunosupresorModerada

    Mycophenolate mofetil may reduce effectiveness of oral contraceptives. (etiqueta de Micofenolato, Interacciones medicamentosas)

  • NevirapinaantirretroviralModerada

    When these oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored. (etiqueta de Nevirapina, Interacciones medicamentosas)

  • NintedanibModerada

    Advise women taking oral hormonal contraceptives experiencing vomiting, diarrhea, or other conditions where the drug absorption may be reduced to use alternative highly effective contraception. (etiqueta de Nintedanib, Advertencias y precauciones)

  • Nirmatrelvir y ritonavirantiviralModerada

    Hormonal contraceptive ethinyl estradiol ↓ ethinyl estradiol An additional, non-hormonal method of contraception should be considered during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID. (etiqueta de Nirmatrelvir y ritonavir, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralModerada

    Effects of Other Drugs on Combined Oral Contraceptives Substances decreasing the plasma concentrations of COCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding. (etiqueta de Norgestimato y etinilestradiol, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralModerada

    Effects of Other Drugs on Combined Oral Contraceptives Substances decreasing the plasma concentrations of COCs and potentially diminishing the efficacy of COCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase… (etiqueta de Norgestrel y etinilestradiol, Interacciones medicamentosas)

  • OctreotidaModerada

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (etiqueta de Octreotida, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoModerada

    Oral Contraceptive: TRILEPTAL may decrease the effectiveness of hormonal contraceptives ( 7.3 ) (etiqueta de Oxcarbazepina, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Moderada

    A Grade ≥3 decrease in neutrophil counts was reported in 66% of patients receiving IBRANCE plus letrozole in PALOMA-2 and 66% of patients receiving IBRANCE plus fulvestrant in PALOMA-3. (etiqueta de Palbociclib, Advertencias y precauciones)

  • PerampanelanticonvulsivoModerada

    Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) (etiqueta de Perampanel, Interacciones medicamentosas)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    …somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

  • Pitolisantfármaco que prolonga el intervalo QTModerada

    Sensitive CYP3A4 Substrates (including hormonal contraceptives): WAKIX may reduce effectiveness of sensitive CYP3A4 substrates. (etiqueta de Pitolisant, Interacciones medicamentosas)

  • PrednisolonacorticosteroideModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect. (etiqueta de Prednisolona, Interacciones medicamentosas)

  • PrednisonacorticosteroideModerada

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Prednisona, Interacciones medicamentosas)

  • QuininaantipalúdicoModerada

    Oral Contraceptives (Estrogen, Progestin) In 7 healthy females who were using single-ingredient progestin or combination estrogen-containing oral contraceptives, the pharmacokinetic parameters of a single 600 mg dose of quinine sulfate were not altered in comparison to those observed in 7 age-matched female control subjects not using oral contraceptives. (etiqueta de Quinina, Interacciones medicamentosas)

  • RifampicinaantibióticoModerada

    Telaprevir Decrease AUC by 92% Systemic Hormonal Contraceptives Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine… (etiqueta de Rifampicina, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    Hormonal Contraceptives PRIFTIN may reduce the effectiveness of hormonal contraceptives. (etiqueta de Rifapentina, Interacciones medicamentosas)

  • RiluzolModerada

    The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with TIGLUTIK may increase the risk of TIGLUTIK - associated adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Riluzol, Interacciones medicamentosas)

  • RitonavirantirretroviralModerada

    Oral Contraceptives or Patch Contraceptives: ethinyl estradiol ↓ ethinyl estradiol Alternate methods of contraception should be considered. (etiqueta de Ritonavir, Interacciones medicamentosas)

  • RivaroxabánanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

  • Roflumilastinhibidor de la PDE4Moderada

    Oral Contraceptives Containing Gestodene and Ethinyl Estradiol The co-administration of DALIRESP (500 mcg) with oral contraceptives containing gestodene and ethinyl estradiol may increase roflumilast systemic exposure and may result in increased side effects. (etiqueta de Roflumilast, Interacciones medicamentosas)

  • Ropinirolagonista de la dopaminaModerada

    Estrogens Population pharmacokinetic analysis revealed that higher doses of estrogens (usually associated with hormone replacement therapy) reduced the clearance of ropinirole. (etiqueta de Ropinirol, Interacciones medicamentosas)

  • SomatropinaModerada

    Oral Estrogen Clinical Impact: Oral estrogens may reduce the serum IGF-1 response to HUMATROPE. (etiqueta de Somatropina, Interacciones medicamentosas)

  • Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (etiqueta de Subcitrato de bismuto, metronidazol y tetraciclina, Interacciones medicamentosas)

  • SugammadexModerada

    Therefore, the administration of a bolus dose of BRIDION is considered to be equivalent to missing dose(s) of oral contraceptives containing an estrogen or progestogen. (etiqueta de Sugammadex, Interacciones medicamentosas)

  • Suxametonio (succinilcolina)bloqueador neuromuscularModerada

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (etiqueta de Suxametonio (succinilcolina), Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Moderada

    …contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives (e.g., a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, an intrauterine system) during JOURNAVX treatment and… (etiqueta de Suzetrigina, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    Mild or Moderate CYP3A Inhibitors: Clotrimazole, antibiotics (e.g., verapamil, diltiazem, nifedipine, nicardipine), amiodarone, danazol, ethinyl estradiol, cimetidine, lansoprazole and omeprazole May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see Warnings and… (etiqueta de Tacrolimus, Interacciones medicamentosas)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosModerada

    Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (etiqueta de Tamoxifeno, Advertencias y precauciones)

  • TeofilinametilxantinaModerada

    Estrogen Estrogen containing oral contraceptives decrease theophylline clearance in a dose-dependent fashion. (etiqueta de Teofilina, Interacciones medicamentosas)

  • TeriflunomidainmunosupresorModerada

    Effect of AUBAGIO on Oral Contraceptives AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. (etiqueta de Teriflunomida, Interacciones medicamentosas)

  • Tetrabenazinainhibidor de VMAT2Moderada

    Chronic increase in serum prolactin levels (although not evaluated in the tetrabenazine development program) has been associated with low levels of estrogen and increased risk of osteoporosis. (etiqueta de Tetrabenazina, Advertencias y precauciones)

  • Tirzepatidaagonista del receptor de GLP-1Moderada

    Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

  • TocilizumabinmunosupresorModerada

    Exercise caution when coadministering TOFIDENCE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. (etiqueta de Tocilizumab, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoModerada

    Patients taking estrogen-containing or progestin-only contraceptives should be asked to report any change in their bleeding patterns. (etiqueta de Topiramato, Interacciones medicamentosas)

  • TriamcinolonacorticosteroideModerada

    Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (etiqueta de Triamcinolona, Interacciones medicamentosas)

  • UlipristalModerada

    Advise women to follow the instructions on the initiation or resumption of hormonal contraceptives after ella intake [see Dosage and Administration(2.2) ]. (etiqueta de Ulipristal, Advertencias y precauciones)

  • WarfarinaanticoagulanteModerada

    Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use. (etiqueta de Fulvestrant, Advertencias y precauciones)

Menciones leves (39)

  • AcarbosaantidiabéticoLeve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (etiqueta de Acarbosa, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCLeve

    Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with NUVIGIL and for one month after discontinuation of NUVIGIL treatment. (etiqueta de Armodafinilo, Interacciones medicamentosas)

  • BexarotenoretinoideLeve

    Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

  • Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (etiqueta de Ciclosilicato de sodio y zirconio, Interacciones medicamentosas)

  • ClobazambenzodiazepinaLeve

    Effect of SYMPAZAN ® on Other Drugs Hormonal Contraceptives SYMPAZAN ® is a weak CYP3A4 inducer. (etiqueta de Clobazam, Interacciones medicamentosas)

  • ClozapinaantipsicóticoLeve

    Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. (etiqueta de Clozapina, Interacciones medicamentosas)

  • Dapagliflozina y metforminainhibidor de SGLT2Leve

    These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Dapagliflozina y metformina, Interacciones medicamentosas)

  • Demeclociclinaantibiótico del grupo de las tetraciclinasLeve

    Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. (etiqueta de Demeclociclina, Interacciones medicamentosas)

  • Dihidroergotaminaalcaloide ergóticoLeve

    Oral Contraceptives The effect of oral contraceptives on the pharmacokinetics of Dihydroergotamine Mesylate Injection, USP has not been studied. (etiqueta de Dihidroergotamina, Interacciones medicamentosas)

  • Doxiciclinaantibiótico del grupo de las tetraciclinasLeve

    Concurrent use of tetracyclines, including doxycycline hyclate may render oral contraceptives less effective. (etiqueta de Doxiciclina, Interacciones medicamentosas)

  • EfavirenzantirretroviralLeve

    Hormonal contraceptives: Oral Ethinyl estradiol/ Norgsetimate Implant Etonogestrel ↑ active metabolites of norgestimate * ↓ etonogestrel A reliable method of barrier contraception should be used in addition to hormonal contraceptives. (etiqueta de Efavirenz, Interacciones medicamentosas)

  • Hormonal contraceptives: Oral Ethinyl estradiol/ Norgestimate ↓ active metabolites of norgestimate A reliable method of barrier contraception should be used in addition to hormonal contraceptives. (etiqueta de Efavirenz, lamivudina y tenofovir, Interacciones medicamentosas)

  • Empagliflozina y metforminainhibidor de SGLT2Leve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Empagliflozina y metformina, Interacciones medicamentosas)

  • GlibenclamidasulfonilureaLeve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Glibenclamida, Interacciones medicamentosas)

  • Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Glibenclamida y metformina, Interacciones medicamentosas)

  • Glipizida y metforminasulfonilureaLeve

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Glipizida y metformina, Precauciones)

  • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (etiqueta de Gluconato de calcio, Interacciones medicamentosas)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (etiqueta de Insulina regular (humana), Interacciones medicamentosas)

  • IsotretinoínaretinoideLeve

    Oral Contraceptives Isotretinoin Capsules did not result in clinically significant changes in the pharmacokinetics of norethindrone and ethinyl estradiol when used concomitantly with a norethindrone and ethinyl estradiol oral contraceptive [see Clinical Pharmacology ( 12.3 )]. (etiqueta de Isotretinoína, Interacciones medicamentosas)

  • LevetiracetamanticonvulsivoLeve

    Potential pharmacokinetic interactions of or with levetiracetam were assessed in clinical pharmacokinetic studies (phenytoin, valproate, warfarin, digoxin, oral contraceptive, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients. (etiqueta de Levetiracetam, Interacciones medicamentosas)

  • Linagliptina y metforminainhibidor de la DPP-4Leve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Linagliptina y metformina, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralLeve

    Contraceptive: ethinyl estradiol* ↓ ethinyl estradiol Because contraceptive steroid concentrations may be altered when KALETRA is co-administered with oral contraceptives or with the contraceptive patch, alternative methods of nonhormonal contraception are recommended. (etiqueta de Lopinavir y ritonavir, Interacciones medicamentosas)

  • MetforminabiguanidaLeve

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Metformina, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoLeve

    Drug interaction studies were conducted in adult patients to investigate the effect of coadministered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of coadministered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives) [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Mirabegrón, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCLeve

    Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with PROVIGIL and for one month after discontinuation of PROVIGIL treatment. (etiqueta de Modafinilo, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoLeve

    Moderate and weak CYP3A4 inhibitors include alprozalam, ameprenavir, amiodarone, aprepitant, atazanavir, cimetidine, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinuprestin/dalfopristin, valproic acid, and verapamil. (etiqueta de Nimodipino, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralLeve

    Changes in Contraceptive Effectiveness Associated with Co-Administration of Other Products If a woman on hormonal contraceptives takes a drug or herbal product that induces enzymes, including CYP3A4, that metabolize contraceptive hormones, counsel her to use additional contraception or a different method of contraception. (etiqueta de Noretisterona y etinilestradiol, Interacciones medicamentosas)

  • Pilocarpinaagonista colinérgicoLeve

    …performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (etiqueta de Pilocarpina, Interacciones medicamentosas)

  • Pioglitazona y metforminatiazolidinedionaLeve

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Pioglitazona y metformina, Interacciones medicamentosas)

  • PregabalinaanticonvulsivoLeve

    No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenytoin, topiramate, and valproic acid. (etiqueta de Pregabalina, Interacciones medicamentosas)

  • RepaglinidameglitinidaLeve

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (etiqueta de Repaglinida, Interacciones medicamentosas)

  • RisedronatobisfosfonatoLeve

    Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etiqueta de Risedronato, Interacciones medicamentosas)

  • RufinamidaanticonvulsivoLeve

    Hormonal contraceptives may be less effective with BANZEL; use additional non-hormonal forms of contraception ( 7.3 ) (etiqueta de Rufinamida, Interacciones medicamentosas)

  • Saxagliptina y metforminainhibidor de la DPP-4Leve

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Saxagliptina y metformina, Interacciones medicamentosas)

  • Sitagliptina y metforminainhibidor de la DPP-4Leve

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Sitagliptina y metformina, Interacciones medicamentosas)

  • TerbinafinaantifúngicoLeve

    There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (etiqueta de Terbinafina, Interacciones medicamentosas)

  • Tetraciclinaantibiótico del grupo de las tetraciclinasLeve

    Concurrent use of tetracycline may render oral contraceptives less effective. (etiqueta de Tetraciclina, Interacciones medicamentosas)

  • Tigeciclinaantibiótico del grupo de las tetraciclinasLeve

    Oral Contraceptives Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective. (etiqueta de Tigeciclina, Interacciones medicamentosas)

  • ZiprasidonaantipsicóticoLeve

    Oral Contraceptives In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components. (etiqueta de Ziprasidona, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (16)

  • AcebutololbetabloqueanteSin interacción

    No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed. (etiqueta de Acebutolol, Interacciones medicamentosas)

  • AlosetrónSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • DarifenacinaanticolinérgicoSin interacción

    Combination oral contraceptives Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of the combination oral contraceptives containing levonorgestrel and ethinyl estradiol [see Clinical Pharmacology (12.3)] . (etiqueta de Darifenacina, Interacciones medicamentosas)

  • DofetilidaantiarrítmicoSin interacción

    Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (etiqueta de Dofetilida, Interacciones medicamentosas)

  • DoravirinaantirretroviralSin interacción

    …clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] . (etiqueta de Doravirina, Interacciones medicamentosas)

  • Emtricitabina y tenofovirantirretroviralSin interacción

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)

  • Emtricitabina, rilpivirina y tenofovirantirretroviralSin interacción

    No clinically significant drug interactions have been observed between TDF and the following medications: entecavir, methadone, oral contraceptives, ribavirin, sofosbuvir, or tacrolimus in studies conducted in healthy subjects. (etiqueta de Emtricitabina, rilpivirina y tenofovir, Interacciones medicamentosas)

  • FesoterodinaanticolinérgicoSin interacción

    Oral Contraceptives In the presence of fesoterodine, there are no clinically significant changes in the plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgestrel [see Clinical Pharmacology (12.3) ] . (etiqueta de Fesoterodina, Interacciones medicamentosas)

  • Ledipasvir y sofosbuvirantiviralSin interacción

    …sofosbuvir is used with the following drugs [see Clinical Pharmacology (12.3) ]: abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, dolutegravir, efavirenz, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, lamivudine, methadone, midazolam, oral contraceptives, pravastatin, raltegravir, rilpivirine, tacrolimus, or verapamil. (etiqueta de Ledipasvir y sofosbuvir, Interacciones medicamentosas)

  • Montelukastantagonista de los receptores de leucotrienosSin interacción

    No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (etiqueta de Montelukast, Interacciones medicamentosas)

  • RaltegravirantirretroviralSin interacción

    Drugs without Clinically Significant Interactions with ISENTRESS In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine, tenofovir, etravirine, darunavir/ritonavir, or boceprevir. (etiqueta de Raltegravir, Interacciones medicamentosas)

  • RizatriptántriptánSin interacción

    Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (etiqueta de Rizatriptán, Interacciones medicamentosas)

  • Sofosbuvir y velpatasvirantiviralSin interacción

    …clinically significant drug interactions have been observed with the following drugs [see Clinical Pharmacology (12.3) ]: VOSEVI: cobicistat, darunavir, elvitegravir, emtricitabine, ethinyl estradiol/norgestimate, gemfibrozil, rilpivirine, ritonavir, tenofovir alafenamide, voriconazole Sofosbuvir/velpatasvir: dolutegravir, ketoconazole, raltegravir Sofosbuvir:… (etiqueta de Sofosbuvir y velpatasvir, Interacciones medicamentosas)

  • TiagabinaanticonvulsivoSin interacción

    Oral Contraceptives : Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of child-bearing age. (etiqueta de Tiagabina, Interacciones medicamentosas)

  • Zafirlukastantagonista de los receptores de leucotrienosSin interacción

    In a single-blind, parallel-group, 3-week study in 39 healthy female subjects taking oral contraceptives, 40 mg twice daily of zafirlukast had no significant effect on ethinyl estradiol plasma concentrations or contraceptive efficacy. (etiqueta de Zafirlukast, Precauciones)

  • Zileutóninhibidor de CYP1A2Sin interacción

    Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (etiqueta de Zileutón, Interacciones medicamentosas)

Compruebe Fulvestrant frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.